Metvix

Methyl Aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a 16% w/w cream for topical use. It is indicated for the treatment of actinic keratosis, a precancerous skin lesion caused by chronic ultraviolet exposure, in adult patients with sun‑damaged skin.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑approved quality for dermatology departments and outpatient settings. The company ensures regulatory conformity, batch traceability and reliable logistics for global distribution.

Metvix is employed in dermatology for photodynamic therapy targeting actinic keratosis, a precancerous skin condition resulting from chronic UV damage. The treatment involves applying the cream to the lesion(s) and activating it with a specific light source, leading to selective destruction of abnormal cells while sparing surrounding healthy tissue.

- Actinic keratosis: clears dysplastic keratinocytes, reduces lesion count and helps prevent progression to squamous cell carcinoma.

Common Side Effects: - Pain at the application site during illumination - Redness (erythema) of treated skin - Swelling (edema) around the treated area - Crusting or scaling of the skin - Itching or burning sensation - Temporary hyperpigmentation

Serious or Rare Side Effects: - Severe photosensitivity reactions extending beyond the treated field - Secondary infection of the treated area - Persistent scarring or ulceration - Allergic dermatitis or hypersensitivity reaction - Systemic symptoms such as fever or malaise - Unusual pigmentary changes or hypopigmentation

Before using Metvix, consider the following precautions: - Patient selection: ensure the patient has confirmed actinic keratosis and no contraindicating skin conditions. - Light protection: advise avoidance of direct sunlight and artificial UV sources for at least 48 hours after treatment. - Application area: apply only to intact skin lesions; avoid mucous membranes and open wounds. - Concomitant photosensitizers: discontinue systemic photosensitizing drugs (e.g., tetracyclines) before therapy. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at room temperature: keep the cream in the original container, protect from light and moisture.

Metvix may interact with other agents that affect photosensitivity or skin healing.

Major Interactions (Avoid): - Systemic photosensitizing drugs such as tetracyclines, sulfonamides, or retinoids. - Recent exposure to strong UV light or phototherapy. - Use of other topical photosensitizers on the same area.

Moderate Interactions (Monitor Closely): - Topical corticosteroids applied before or after treatment may reduce efficacy. - Concurrent use of wound‑healing agents that could alter skin response. - Herbal supplements with photosensitizing potential (e.g., St. John’s wort).